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Scaphoid fractures account for 90% of carpal fractures and occur predominantly in young 106 
men. Immediate surgical fixation of this fracture has increased, in spite of insufficient 107 
evidence of improved outcomes over non-surgical management. We compared the clinical 108 
effectiveness of surgical fixation with cast immobilization and early fixation of those that fail 109 
to unite, for ≤2 mm displaced scaphoid waist fractures in adults. 110 
 111 
Methods 112 
This pragmatic, multicentre, open-label, parallel-group, two-arm randomised clinical trial 113 
included adults who presented to orthopaedic departments of 31 hospitals in England and 114 
Wales with a clear, bicortical fracture of the scaphoid waist on radiographs. Participants were 115 
randomly assigned to early surgical fixation or below-elbow cast immobilization followed by 116 
immediate fixation of confirmed non-union. The primary outcome was the Patient Rated 117 




Of 439 randomised patients (mean age 33 years, 363 [83%] men), 408 (93%) were included 122 
in the primary analyses. There was no difference in PRWE score at 52 weeks (adjusted mean 123 
difference -2·1 points, 95% CI -5·8 to 1·6, p=0·27). There were no differences at 52 weeks 124 
for the PRWE pain or function subscales. More participants in the surgery group experienced 125 
a surgery-related potentially serious complication than in the cast group (n=31, 14% vs n=3, 126 
1%), but fewer had cast-related complications (n=5, 2% vs n=40, 18%). The number 127 
experiencing a medical complication (n=4, 2% vs n=5, 2%) was similar in the two groups.” 128 
 129 
Interpretation 130 
Adult patients with ≤2 mm displaced scaphoid waist fracture should have initial cast 131 
immobilization and suspected non-unions confirmed and immediately fixed. This will help 132 
avoid risks of surgery and mostly limit its use to fixing non-union.  133 
 134 
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This project was funded by the National Institute for Health Research Health Technology 136 
Assessment Programme (project number 11/36/37). 137 
 138 
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Research in Context: 141 
 142 
Evidence Before this study:  143 
Fracture of the scaphoid bone (one of eight small bones in the wrist) is common in young 144 
active people and typically caused by a fall on the hand or the hand being suddenly forced 145 
backwards. Traditionally the treatment has been to rest the wrist in a plaster cast for six to ten 146 
weeks and allow the broken bone to heal. The one in ten that do not heal are then operated on 147 
and held still with a screw. In recent years, another way of holding these fractures still while 148 
they heal has been to operate early on the wrist and to fix the broken bone with a special 149 
screw. While there has been an increasing trend to perform more costly and invasive surgery, 150 
which also has a bigger impact on service delivery and use of theatre time, compared to a 151 
minimal intervention of cast immobilisation, there is inconclusive evidence that it produces 152 
better patient outcomes. 153 
 154 
In February 2018, a systematic review and meta-analyses was conducted of surgery 155 
compared with nonsurgical treatment for scaphoid waist fracture with slight or no 156 
displacement. PubMed, Embase and Cochrane Library were searched and the references for 157 
relevant reviews and systematic reviews were manually retrieved. The keywords used were 158 
“scaphoid bone”, “fractures, bone” and “surgical procedures, operative” and synonyms for 159 
these terms. There were 14 eligible studies, including 10 RCTs and 4 cohort studies, that 160 
included 765 patients. The evidence was of variable quality and showed that there was no 161 
difference in patient satisfaction, pain, and patient-reported outcomes between surgical 162 
treatment and cast immobilisation. Although there was evidence that surgical treatment could 163 
reduce the incidence of non-union and shorten the time to union. The need for high-quality 164 
studies was recommended.  165 
 166 
We undertook a rigorously designed, and sufficiently powered, randomised, pragmatic, 167 
parallel group, two-arm, superiority trial called SWIFFT to determine whether surgical 168 
fixation compared with cast immobilization and early fixation only of those that fail to unite 169 
for ≤2 mm displaced scaphoid waist fractures in adults improved patient outcomes. 170 
 171 
Added value of this study: 172 
 6 
To our knowledge, SWIFFT is the largest randomised trial (439 participants) to compare 173 
surgery with cast immobilisation in the treatment of adults with sight or no displacement of 174 
scaphoid waist fractures. It has doubled the evidence from previous small trials of variable 175 
quality. There was no evidence of a difference in overall patient-reported outcome at 52 176 
weeks, nor for the pain or function sub-scales of the patient-reported outcome, grip strength, 177 
or range of movement. Time off work was similar between the two groups. While fewer 178 
participants in the surgery group (n=4, 2%) compared with cast immobilization (n=9, 4%) 179 
had non- or slight union at 52 weeks (p=0·13), surgery was more likely to lead to potentially 180 
serious complications. 181 
 182 
Implications of all the available evidence:  183 
This large and rigorous trial found little difference between the two management pathways 184 
for scaphoid waist fractures displaced ≤ 2mm, across a range of outcomes. These findings are 185 
timely as we see an increasing trend towards primary surgical fixation, which is not clearly 186 
supported by this evidence. Cast immobilization treatment is as effective, provided that 187 
suspected non-unions are confirmed early and fixed. The numbers of scaphoid fractures to 188 
surgically fix to avoid one non-union was estimated to be 73. Early fixation, therefore, could 189 
be restricted for displaced fractures that are >2mm to limit exposure to surgical risks and 190 
make better use of theatre time. These results should be shared with patients when discussing 191 












Scaphoid fractures account for 90% of carpal fractures and 2-7% of all fractures.1 It is an 204 
important public health problem as it predominantly affects young active individuals (mean 205 
age 29 years)2 in their most productive working years. The scaphoid fractures are typically 206 
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caused when the wrist is suddenly extended either when putting the hand out to break a fall or 207 
when the palm is struck forcibly by an object. Most (64%) involve the waist (middle 60%) of 208 
the scaphoid.3 A scaphoid fracture is considered displaced if there is a step or gap of 1 mm or 209 
more.4 Scaphoid fractures disrupt the proximal carpal row and alter how the wrist is stabilised 210 
to permit the hand and digits to function efficiently. 211 
 212 
The aim of treatment is to stabilise the fracture to permit healing by either immobilising the 213 
wrist in a cast or passing a screw across the fracture. About 10-15% of undisplaced or 214 
minimally displaced fractures do not heal in a cast.5 At present the evidence of treatment of 215 
displaced fractures is weak and recommendations are based on case-series. When 216 
displacement of the fracture is more than 2 mm most clinicians would prefer to reduce the 217 
fracture. Non-union, if untreated, almost inevitably leads to arthritis, usually within five 218 
years.6 This causes symptoms of pain and stiffness at a young age. Therefore, the standard 219 
non-operative pathway is to fix a fracture that has not healed after initial cast 220 
immobilisation.2 221 
 222 
Immediate surgical fixation is said to avoid the need for a cast and accelerate return to 223 
function, work, and sport7 but exposes patients to surgical risks. Eight small randomised 224 
clinical trials in United Kingdom, United States of America (USA) and Sweden,8 of variable 225 
quality, reporting on undisplaced or minimally displaced fractures of the scaphoid waist, 226 
provide unclear evidence on whether surgical fixation gives better outcomes than cast 227 
immobilization. Despite insufficient evidence there is an increasing trend9 to immediately fix 228 
this fracture for perceived short-term benefits, but concerns remain about the lack of evidence 229 
on long-term benefits and additional risks from surgery, such as malunion, infection, and 230 
implant related problems. 231 
 232 
The Scaphoid Waist Internal Fixation for Fractures Trial (SWIFFT) was designed to compare 233 




Study design and participants 238 
This was a pragmatic, open-label, multicentre, stratified, parallel-group, superiority, 239 
randomised clinical trial. Patients were recruited between July 2013 and July 2016 from 240 
 8 
orthopaedic departments at 31 United Kingdom (UK) National Health Service (NHS) 241 
hospitals. Follow-up was to 52 weeks post-randomisation for all patients. 242 
 243 
Patients were eligible if they were skeletally mature, aged 16 years or older, and presented to 244 
the NHS within two weeks of injury with a clear bicortical scaphoid waist fracture on plain 245 
radiographs and could have surgery within two weeks of presentation. A bicortical fracture 246 
was defined as when on any radiographic view the continuity of both cortices were broken. 247 
Displaced fractures with ≤2 mm step or gap on any of five radiographic views (posterior-248 
anterior, lateral, semi-supine, semi-prone, elongated-scaphoid) were included. Both the 249 
assessment of whether the fracture was bicortical or displaced was undertaken by the 250 
clinician establishing eligibility at the recruiting site. A research CT scan done at baseline, 251 
including the radiographs, were reviewed independently by two senior consultant radiologists 252 
and a senior orthopaedic surgeon (Chief Investigator) who used standardised criteria to help 253 
confirm fracture eligibility. 254 
 255 
Patients were excluded if fractures had displacement >2 mm or involved the proximal or 256 
distal pole, they had a trans-scaphoid-perilunate dislocation, multiple injuries in the same 257 
limb, concurrent wrist fracture in the opposite limb, or insufficient mental capacity to comply 258 
with treatment or data collection, they were pregnant, or not resident in a participating site’s 259 
catchment area to allow follow-up.  260 
 261 
The study and all amendments were approved by the Research Ethics Committee – East 262 
Midlands (REC reference 13/EM/0154). The published trial protocol,10 and the analysis plan 263 
are available (Supplement 1). The trial was overseen by independent steering and data 264 
monitoring and ethics committees. 265 
 266 
Randomisation and blinding 267 
Surgeons confirmed eligibility. After providing consent and baseline information, patients 268 
were allocated (1:1) randomly by hospital staff to one of the two treatment groups using an 269 
independent remote randomisation service (York Trials Unit, YTU, University of York).  270 
 271 
Randomisation was stratified, using random block sizes of six and twelve, by whether or not 272 
there was displacement of either a step or gap of 1-2 mm inclusive on any radiographic view.  273 
 274 
 9 
Registering participants before remote computer-generated randomisation with randomly 275 
varying block sizes ensured allocation concealment.  276 
 277 
It was not possible to blind trial participants or clinicians for outcome assessments. To 278 
minimise bias in bone union assessment, all radiographs and Computed Tomography (CT) 279 
scans were reviewed independently by two consultant musculoskeletal radiologists and a 280 
consultant orthopaedic surgeon (Chief Investigator) and disagreements resolved through 281 




Surgical treatment was by percutaneous or open surgical fixation depending on the surgeon’s 286 
preferred technique. Standard CE marked headless compression screws were used.2 The type 287 
of implant used was not restricted nor was the surgical approach or the postoperative care.  288 
 289 
The comparator was below elbow cast immobilization for six to ten weeks, with or without 290 
inclusion of the thumb.5 If non-union was suspected based on the clinical judgement of an 291 
experienced surgeon at the recruiting site, rather than defined criteria, on six to 12- week 292 
radiographs, it was investigated using CT and, if confirmed, immediate surgical fixation 293 
offered. The surgical procedure to treat a non-union was as described above.2 This pathway is 294 
referred to as the “cast immobilization” group. 295 
 296 
All participants received standardised, written physiotherapy advice detailing rehabilitation 297 
exercises. Additional rehabilitation was at the treating clinician's discretion. 298 
 299 
Data collection and outcome measures 300 
Participant-completed questionnaires were collected in the hospital at baseline and we asked 301 
about their wrist problem for the week before injury; and completed at six, 12, 26, and 52 302 
weeks post-randomisation by post, in hospital clinic or by telephone.  303 
 304 
The primary outcome was the Patient Rated Wrist Evaluation (PRWE) total score. The 305 
PRWE measures wrist pain and disability.11 It contains 15 items, each with a ten-point 306 
ordered scale, and the total score range is from 0 (no disability) to 100. The primary end-307 
point was 52 weeks.  308 
 10 
Secondary outcomes were the PRWE subscale scores of pain and function, the Short Form 12 309 
(SF-12) health survey physical and mental component scores,12 bone union, range of 310 
movement, grip strength, and complications.  311 
 312 
Bone union was determined using the plain radiographs and a CT scan performed for 313 
research purposes at baseline and 52 weeks. Routine radiographs taken at six and 12-week 314 
hospital clinic visits were also collected. Union was defined as complete disappearance of the 315 
fracture line5 on radiographs and complete bridging on CT scans.13 Partial union was 316 
recorded as the proportion of the fracture plane traversed by bridging trabeculae on CT 317 
sagittal and coronal multiplanar scaphoid reconstructions and union was categorised as none 318 
(0%), slight (>0-20%), partial (>20-70%), almost full (70-<100%) and full (100%). Malunion 319 
was assessed on the 52-week CT scan, as the ratio of Scaphoid height to length ≥0·6 or ≥0·7 320 
in the scaphoid sagittal plane.14  321 
 322 
The range of movement of both wrists was measured using a goniometer and grip strength of 323 
both hands using a calibrated Jamar dynamometer at baseline and at six, 12, and 52 weeks 324 
post-randomisation, during hospital visits.  325 
 326 
Complications, defined as medical, surgical, or cast related, were recorded at six, 12 and 52-327 
week hospital visits. Participants reported the number of injury-related days off work. Data 328 
on details of surgery were also collected. 329 
 330 
Statistical methods 331 
A six-point improvement in PRWE score was deemed a conservative15 minimum clinically 332 
important difference. Using a SD of 20,11 this gave an effect size of 0·3. To observe this 333 
effect size with 80% power using a two-sided 5% significance level requires 350 participants. 334 
Allowing for 20% attrition, the recruitment target was 438 participants.  335 
 336 
Analyses strictly followed a prespecified analysis plan, endorsed by the independent 337 
oversight committees. Analyses were on an intention-to-treat basis, and were performed in 338 
Stata v1516 using two-sided statistical tests at the 5% significance level. Baseline and 339 
outcome data are summarized descriptively by treatment group.  The primary analysis 340 
compared total PRWE scores between the two groups using a covariance pattern, mixed-341 
effect linear regression model incorporating all post-randomisation time points (six, 12, 26 342 
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and 52 weeks). Treatment group, time point, treatment-by-time interaction, age, baseline 343 
fracture displacement (< 1mm/1-2mm), and dominance of injured limb were fixed effects. 344 
Participant was a random effect accounting for repeated observations per patient. An 345 
unstructured covariance pattern for the correlation between the observations for a participant 346 
over time was specified (based on minimizing the Akaike’s information criterion).17 347 
Diagnostics of model fit revealed that the standardised residuals demonstrated sufficient 348 
normality and were uniform against fitted values. Estimates of the difference in total PRWE 349 
score were extracted for each time point and overall, with 95% confidence intervals (CI) and 350 
p-values.   351 
 352 
Any response bias was minimised by using a repeated-measures model in the primary 353 
analysis, which allowed inclusion of intermittent responders. Multiple imputation by chained 354 
equations assessed the effect of missing data.18  355 
 356 
Adding smoking status (yes/no) to the primary model (post-hoc analysis reflecting a chance 357 
imbalance at baseline) and adding centre as a random effect to explore for potential clustering 358 
were undertaken as sensitivity analyses. To account for non-compliance (surgery to cast 359 
immobilization) and contamination (cast immobilization to surgery) a complier average 360 
causal effect (CACE) analysis was conducted using two-stage least squares, with randomised 361 
treatment as the instrumental variable.19 Further sensitivity analyses are in supplementary 362 
material. 363 
 364 
We planned three subgroup analyses: one exploring patient treatment preferences at baseline 365 
and two exploring fracture displacement as recorded at randomisation or corrected after 366 
Study Eligibility Form review. Greater benefit of surgery was expected in i) participants with 367 
a baseline preference for surgery, and ii) in patients with a displaced fracture. 368 
 369 
Analyses of the secondary outcomes was as described for the primary outcome. Bone union 370 
at 52 weeks was dichotomised as “possibly needing surgery” (0-20% united), and “not 371 
requiring surgery” (>20%-100% union) and compared between groups using logistic 372 
regression adjusting for age, fracture displacement, and dominant hand. Malunion was 373 
presented overall and for each treatment group at six, 12 and 52 weeks (Supplementary Table 374 
5). The presence of medical, surgical, or cast complications was analysed by logistic 375 
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regression, adjusting for age, hand dominance, and fracture displacement. All serious and 376 
non-serious adverse events were summarised by treatment group. 377 
 378 
Role of the funding source 379 
The funders monitored the trial progress but had no role in study design, data collection, data 380 
analysis, data interpretation, or writing or approving or the decision to submit the publication. 381 
The corresponding author had full access to all the data in the study and had final 382 
responsibility for the decision to submit for publication. 383 
 384 
Results 385 
We identified 775 eligible patients and 439 (57%) were recruited (Figure 1) across 31 sites 386 
(median 10 patients per site, range 1-61). Most (n=325, 97%) of the 336 patients who did not 387 
consent to the study despite being eligible gave a reason, and most were accounted for by: 388 
preference for non-operative treatment (n=206); preference for surgery (n=40); or unable to 389 
commit to follow-ups (n=24). Participants who gave consent were randomly allocated to 390 
surgery (n=219) or cast immobilization (n=220). 391 
 392 
The mean age was 33 years (range 16-80), 363 (83%) were male (Table 1) and 269 (61%) 393 
had fracture displacement <1 mm (Supplementary Table 1). These characteristics were 394 
similar to the 336 patients who refused consent (mean age 32 years, n=268, 80% male), 395 
whereas ineligible patients (n=272) were older (mean age 36 years) with a lower proportion 396 
of males (n=203, 75%) (Supplementary Table 2). The left wrist was injured in 53·1%, and 397 
the non-dominant limb in 55·1% (Supplementary Table 1). 398 
 399 
Baseline characteristics were similar between groups, except for ethnicity, education, and 400 
smoking status (Table 1). 401 
 402 
Of the 219 patients allocated to surgery, 188 (86%) received surgery, on average 10·2 days 403 
(range 3-20) after injury, and performed by 95 surgeons across 29 sites. Data on operating 404 
surgeon were available for 187 of the 188 operations; 163 were either performed (n=120, 405 
64%) or assisted/supervised (n=43, 23%, assisted 40, supervised 3) by consultants. The 406 
remaining 24 were performed by a specialist trainee (n=13) or staff grade/associate specialist 407 
(n=11). Of the 220 patients allocated to cast immobilization, 214 (97%) had a cast initially 408 
and six (3%) received surgery (mean 13·5 days after injury, range 5-32) shortly after 409 
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randomisation (contamination). One of the remaining 214 patients had surgery 29 days after 410 
randomisation due to perceived displacing of the fracture and one had fixation at a non-411 
participating hospital. Following confirmation of non-union, 17 (8%) received surgery, on 412 
average 159 days (range 68-358) after injury. Fourteen of these had surgery within 26 weeks 413 
of randomisation (only five within 12 weeks as per protocol), while three had delayed 414 
surgery. (See Supplementary Tables 3 and 4 for further detail.) 415 
 416 
Following randomisation, participants in the cast immobilization group wore a cast for an 417 
average of 44·8 days (SD 15·2); 91 (41%) then were given a splint for an average of a further 418 
26·4 days (SD 15·1). Of the 188 participants allocated to the surgical fixation arm who 419 
underwent surgery 86% had minimal or no immobilisation: 26 (14%) had a bandage applied 420 
(duration not available); 62 (33%) had a splint only (mean 28·4 [SD 19·6] days); and 73 421 
(39%) had a cast on for a short period immediately after surgery (mean 15·6 [SD 9·8] days) 422 
followed by a splint (24·7 [SD 13·9] days). The remaining (14%) were immobilised in a cast: 423 
24 (13%) had a cast only (mean 30·9 [SD 16·7] days); and three had a splint for a mean of 424 
12·7 days [SD 2·5] then a cast for a mean of 27·7 days [SD 0·6]. 425 
 426 
Primary outcome and sensitivity analyses 427 
Valid PRWE data were provided by 348 participants (79%) at six weeks, 341 (78%) at 12 428 
weeks, 302 (69%) at 26 weeks, and 362 (82%) at 52 weeks. The primary analysis included 429 
408 (93%) participants (203 surgery; 205 cast immobilization) with a valid PRWE score for 430 
at least one follow-up time point and complete covariate data. At 52 weeks, the unadjusted 431 
mean PRWE score was 11·4 (SD 16.6) in the surgery group and 14·2 (SD 19·8) in the cast 432 
immobilization group for which there was no evidence of a ceiling effect. There was no 433 
evidence of a statistically significant or clinically important difference in PRWE score 434 
between groups at 52 weeks (adjusted mean difference -2·1 favouring the surgery group, 435 
95% CI -5·8 to 1·6, p=0·27), at 26 weeks nor over the whole 52 weeks (Table 2; Figure 2). 436 
There was a statistically significant difference at week 12 (p=0·01) and weak evidence of a 437 
difference at six weeks (p=0·06) favouring surgery. While the point estimates of the 438 
difference do not exceed 6 points (the threshold of clinical importance we are using in this 439 
study), the confidence intervals do include this difference.  440 
 441 
Although 83% of participants had provided a PRWE at 52 weeks, PRWE data were missing 442 
for at least one follow-up time-point in 190 participants (43%). Analyses on complete, 443 
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multiply imputed datasets produced similar results to the primary analysis (adjusted mean 444 
difference -2·1, 95% CI -5·9 to 1·6, p=0·26 at 52 weeks) (Supplementary Table 5).  445 
 446 
There was no statistically significant difference in total PRWE score between the treatment 447 
groups at 52 weeks after adjustment for smoking status (p=0·14) or clustering for site 448 
(p=0·31). The other sensitivity analyses did also not alter our primary findings 449 
(Supplementary Table 5).  450 
 451 
The CACE estimate of the treatment effect at 52 weeks was a difference of -3·1 in favour of 452 
the surgery group (95% CI -7·3 to 1·1, p=0·15). Therefore, the non-compliance described did 453 
not have an effect on the primary findings. 454 
 455 
Subgroup analyses 456 
There was no statistically significant interaction between randomised group and treatment 457 
preference, or fracture displacement assessed at either study enrolment or randomisation 458 
(Supplementary Figure 1). 459 
 460 
Secondary outcomes 461 
We found no statistically significant differences between groups at 52 weeks for the PRWE 462 
pain or function subscales, the SF-12 mental component score, range of wrist movement, or 463 
grip strength (Table 2). There was a difference in SF-12 physical component score favouring 464 
the surgery group of 1·6 points (95% CI 0·2 to 3·1, p=0·03). Range of movement and grip 465 
strength are summarised in Supplementary Table 6. 466 
 467 
Participants in the surgery group were less likely to have non- or slight union of their fracture 468 
at 52 weeks (Table 3) but this difference was not statistically significant (four vs nine 469 
participants, adjusted odds ratio 0·40, 95% CI 0·12 to 1·33, p=0·13). Supplementary Table 7 470 
presents the malunion assessed at different thresholds of ratio of scaphoid height to length 471 
(0·6 and 0·7). For both thresholds there were no marked differences between groups in 472 
malunion at all time-points on the radiographic and CT images.    473 
 474 
More participants in the surgery group experienced a surgery-related potentially serious 475 
complication than in the cast group (n=31, 14% vs n=3, 1%), but fewer had cast-related 476 
complications (n=5, 2% vs n=40, 18%). In the surgery group, four experienced nerve events 477 
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(numbness in the region of the scar, n=3 and decreased sensation over the scar and distally 478 
with tenderness, n=1), two had infection, and three developed Complex Regional Pain 479 
Syndrome (CRPS); while in the cast group, one developed transient nerve problems, two had 480 
infection, and none had CRPS (Supplementary Table 8). The number experiencing a medical 481 
complication (n=4, 2% vs n=5, 2%) was similar in the two groups. CT images at 52 weeks 482 
were assessed for screw penetration from the surface of the bones in mm for 142 of the 188 483 
participants who received surgery; screw penetration was identified in 93 (65%) participants 484 
(<1 mm, n=25 [27%]; 1-2 mm inclusive, n=44 [47%]; and >2 mm, n=24 [26%]). For these 485 
142 participants the unadjusted mean PRWE at 52 weeks for those who had screw 486 
penetration <1mm was 8·9 (SD 15·0) and for those ≥1mm was 10·8 (SD 13·9).    487 
 488 
Eight of 219 (4%) participants in the surgery group had 11 re-operations; the re-operations 489 
were to remove prominent screws in six and for non-union in two, with one requiring 490 
scaphoid excision and a four-corner fusion. One of 220 allocated to initial cast 491 
immobilization developed non-union that was fixed but required re-operation for persistent 492 
non-union.  493 
 494 
There were three serious adverse events, one for each of three participants in the surgery 495 
group; all were related to anaesthesia or surgery, and two were unexpected (Supplementary 496 
Table 9). 497 
 498 
Over the 52 week period, surgery group participants reported an average of 15·6 days of lost 499 
employment compared to 18·2 days in the cast immobilization group (Table 4). This 500 
difference is not statistically significant. 501 
 502 
Discussion 503 
Adults who have a bicortical scaphoid waist fracture with 2 mm or less displacement 504 
immobilised in a below elbow cast have little difference in pain and function to those having 505 
the fracture surgically fixed with a screw. Cast immobilisation, with suspected non-unions 506 
identified and fixed early, was successful in delivering fracture union and very substantially 507 
reduced the need for surgery. The differences between groups were below the pre-specified 508 
and conservative six points on the PRWE and therefore unlikely to be important to patients. 509 
Our findings on the intention-to-treat analysis were confirmed by sensitivity analyses 510 
accounting for crossover, and adjusting for fracture displacement, participants’ smoking 511 
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status and clustering at site. Secondary outcomes of bone union, grip strength, range of 512 
movement, and SF-12 support the primary analysis findings. 513 
 514 
Early on, when more participants in the cast group were still in a cast, differences in pain and 515 
function were statistically significant, favouring surgery, but below six points on the PRWE 516 
and so of uncertain clinical relevance. Beyond 12 weeks there was no difference between 517 
groups, nor did this study identify evidence that the rate of non- and slight union was 518 
statistically significantly different between surgical fixation and cast immobilisation. We 519 
observed this state in four (three slight union and one non-union) participants in the surgery 520 
group and nine (five slight union and four non-union) of those who were treated in a plaster 521 
cast. Complications of infection, nerve problems and CRPS were ten-times more likely after 522 
early fixation (14·2%) than in the cast group (1·4%). The screw penetrated joints in far more 523 
participants than anticipated, in half the screw protruded by 1-2 mm and in a quarter by over 524 
2 mms risking irreversible articular cartilage damage and early degenerative arthritis but only 525 
six had penetrating screws removed. In most, screw penetration was seen because we did CT 526 
scans at one year. This emphasises the need for careful imaging during surgery. Cast 527 
complications (soft, tight or broken cast, skin soreness) were minor, resolved early and had 528 
no lasting consequence. Reoperations were more frequent after early screw fixation (4% vs 529 
<1%) for six of these participants the re-operations were for implant related problems and for 530 
two they were for non-union, with one requiring scaphoid excision and a four-corner fusion. 531 
The longer-term consequences of arthritis, malunion, injury, and screw penetration will be 532 
investigated in a five-year review of these participants. 533 
 534 
Over the last few decades the use of surgery has increased as clinicians and patients 535 
anticipated better union rate and quicker return to work. We reviewed Hospital Episode 536 
Statistics (HES) for National Health Service (NHS) hospitals in England.  These recorded a 537 
two-thirds increase (1534, 1720 and 2582) of acute scaphoid fracture fixations for the years 538 
2007/8, 2008/9 and 2009/10 before this study was commissioned. The rate of surgical 539 
fixation20 rose very slightly from 37% to 41% from 2007/8 to 2008/9 but then increased 540 
sharply to 62% in 2009/10. The rate of surgical treatment of acute scaphoid fractures has also 541 
increased significantly in the USA from 22·1% in 2006 to 34·1% in 2012. The incidence of 542 
primary surgical treatment has increased more than threefold in Finland between 1997 and 543 
2014. Achieving union is particularly important since untreated non-union causes wrist 544 
arthritis. The difference in union rate between those fractures initially treated in a cast and 545 
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those fixed with a screw was, however, insignificant. This confirms previous observations.8 546 
The rate of non-union was lower than we anticipated in both groups, possibly due to the 547 
rigour with which the fracture was diagnosed at baseline and the treatment and assessment of 548 
non-union compared with previous evidence. The numbers of scaphoid fractures we need to 549 
fix to avoid one non-union is 73 (95% CI 24 to 100).21 There was no difference between 550 
groups for range of wrist movement or grip strength at 52 weeks confirming previous smaller 551 
reports. 552 
 553 
In contrast to most previous trials,22 we found very little difference in days of lost 554 
employment. This may reflect that around 78% were treated initially in a cast which did not 555 
include the thumb and therefore permitted early use of the hand. Patients may have felt more 556 
secure working in a cast and responded to reassurance regarding return to work in a cast. 557 
As this was a pragmatic trial, surgeons were allowed to follow their usual practice for 558 
immobilisation and use of physiotherapy. Most operations were performed or supervised by 559 
senior surgeons. The number of large and small hospitals and surgeons involved improves 560 
generalisability to a range of clinical settings. The findings are applicable to both participants 561 
with undisplaced fractures and those displaced up to 2 mm. Bias was minimised with the high 562 
rate of questionnaires returned at the primary end point and our analysis model permitted 563 
inclusion of all available data. The large number of participants has doubled the evidence 564 
from previous small trials.23-30  565 
 566 
Limitations include non-compliance, when treatment was not delivered as allocated, which 567 
can underestimate the treatment effect. In the surgery group, 31 patients (14%) did not have 568 
surgery compared with six patients (3%) in the cast group who immediately switched to 569 
surgery. However, analysis accounting for non-compliance supported the results of the 570 
primary analyses. Further non-compliance in the cast immobilisation pathway, of 17 571 
participants who had surgery for early identified non-union, five had it within 12 weeks from 572 
randomisation as anticipated in our protocol and 12 were treated after 12 weeks. Three of the 573 
four participants in the cast group who had a non-union at 52 weeks were not offered surgery. 574 
Even though not all participants in the cast immobilization group who had non-union had it 575 
immediately fixed, participants in the surgery group did not have less pain or better function 576 
at 52 weeks. Although clinicians assessing grip and movement range could not be blinded to 577 
the treatment, multiple clinicians assessed outcomes.  578 
 579 
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Any response bias from imbalance in return rates (lower in the plaster cast group) and 580 
characteristics of a responder, was minimised by using a mixed-effect, repeated measures 581 
model which included intermittent responders which allowed data from 97% of the 582 
participants with an almost identical numbers of participants included for each treatment 583 
group, to be used. The use of this statistical model increased the statistical power of the 584 
analyses, compared with the use of a two sample t-test at a single time point used for the 585 
sample size calculation. 586 
 587 
The pragmatic design of the SWIFFT trial helps to ensure that results are relevant to most 588 
settings. The criteria used to enrol participants in the trial were minimised as much as 589 
possible. Nor were there stringent criteria as to which surgeons could operate on participants. 590 
Those surgeons who did operate, or were present during the operation, were mostly 591 
consultants. The follow-up clinics that were organised at six and 12 weeks were consistent 592 
with routine clinical practice. The follow-up clinic at 52 weeks, which was the primary end-593 
point, was to ensure as much as feasible that participants in both treatment groups had the 594 
time to complete the treatment pathway being delivered. The findings are also applicable to 595 
both participants with undisplaced and ≤2 mm displaced fractures.  596 
 597 
Conclusion 598 
This large and rigorous trial found little difference between the two management pathways 599 
for scaphoid waist fractures displaced ≤2 mm, across a range of outcomes. These findings are 600 
timely as we see an increasing trend towards primary surgical fixation which is not clearly 601 
supported by this evidence. Cast immobilization treatment is as effective, provided that 602 
suspected non-unions are confirmed early and fixed. 603 
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Table 1. Baseline characteristics for all randomised participants and those included in 672 
the primary analysis, by treatment group 673 
 















Sex, No. (%)       
Male 
180 




(82·8) 169 (82·4) 
337 
(82·6) 




(17·2) 36 (17·6) 
71 
(17·4) 
Age, years       
Mean (SD) 
32·9 

















(%)       
White 
205 




(94·1) 180 (87·8) 
371 
(90·9) 
Other 12 (5·5) 25 (11·4) 37 (8·4) 12 (5·9) 25 (12·2) 37 (9·1) 
Missing 2 (0·9) 0 (0·0) 2 (0·5) 0 (0·0) 0 (0·0) 0 (0·0) 
Education, 
No. (%)       
No formal 






















(20·2) 60 (29·3) 
101 
(24·8) 
Missing 3 (1·4) 0 (0·0) 3 (0·7) 1 (0·5) 0 (0·0) 1 (0·2) 
Employment 
status, No. 
(%)       
Part-time 20 (9·1) 18 (8·2) 38 (8·7) 20 (9·9) 18 (8·8) 38 (9·3) 
Full-time 
127 




(58·6) 111 (54·1) 
230 
(56·4) 
Self-employed 21 (9·6) 36 (16·4) 
57 
(13·0) 19 (9·4) 31 (15·1) 
50 
(12·3) 
Student 20 (9·1) 21 (9·5) 41 (9·3) 19 (9·4) 21 (10·2) 40 (9·8) 
Retired 7 (3·2) 5 (2·3) 12 (2·7) 7 (3·4) 5 (2·4) 12 (2·9) 
Looking after 
family/home 1 (0·5) 6 (2·7) 7 (1·6) 0 (0·0) 5 (2·4) 5 (1·2) 
Seeking work 9 (4·1) 5 (2·3) 14 (3·2) 8 (3·9) 5 (2·4) 13 (3·2) 
Other 11 (5·0) 9 (4·1) 20 (4·6) 10 (4·9) 9 (4·4) 19 (4·7) 
Missing 3 (1·4) 0 (0·0) 3 (0·7) 1 (0·5) 0 (0·0) 1 (0·2) 
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(%)       
Yes 












(68·0) 154 (75·1) 
292 
(71·6) 
Missing 3 (1·4) 1 (0·5) 4 (0·9) 1 (0·5) 1 (0·5) 2 (0·5) 
Diabetes, No. 
(%)       
Yes 7 (3·2) 4 (1·8) 11 (2·5) 6 (3·0) 4 (2·0) 10 (2·5) 
No 209 




(96·6) 201 (98·0) 
397 
(97·3) 
Missing 3 (1·4) 0 (0·0) 3 (0·7) 1 (0·5) 0 (0·0) 1 (0·2) 
Steroid use, 
No. (%)       
Yes 6 (2·7) 4 (1·8) 10 (2·3) 6 (3·0) 4 (2·0) 10 (2·5) 
No 210 




(96·6) 201 (98·0) 
397 
(97·3) 
Missing  3 (1·4) 0 (0·0) 3 (0·7) 1 (0·5) 0 (0·0) 1 (0·2) 
a Participants included in primary analysis if they provided valid PRWE data for at least one post-randomisation time 
point and complete covariate data. 
b The “Cast immobilization” group was the standard clinical pathway using cast immobilisation initially and expecting 
suspected non-unions to be confirmed on imaging and immediately fixed. 
SD, standard deviation; PRWE, Patient Rated Wrist Evaluation  
 674 
  675 
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Table 2. Primary and secondary outcomes  676 
 
Mean (95% CI)a 






Primary outcome: PRWE total scorec 
No. of 203 205   
At 6 wk 35·6 (32·6, 38·6) 39·8 (36·8, 42·8) -4·2 (-8·5, 0·1) 0·06 
At 12 wk 21·0 (18·1, 24·0) 26·6 (23·6, 29·6) -5·6 (-9·8, -1·4) 0·01 
At 26 wk 16·2 (13·5, 18·9) 16·5 (13·8, 19·2) -0·3 (-4·1, 3·6) 0·89 
At 52 wk 11·9 (9·2, 14·5) 14·0 (11·3, 16·6) -2·1 (-5·8, 1·6) 0·27 
Over 52 21·3 (18·9, 23·6) 24·4 (22·0, 26·7) -3·0 (-6·3, 0·3) 0·07 
Secondary outcome: PRWE pain subscale scored 
No. of 203 206   
At 6 wk 18·8 (17·3, 20·4) 19·0 (17·5, 20·5) -0·1 (-2·3, 2·0) 0·89 
At 12 wk 13·1 (11·5, 14·6) 15·0 (13·4, 16·6) -2·0 (-4·2, 0·3) 0·09 
At 26 wk 11·0 (9·4, 12·5) 10·6 (9·0, 12·2) 0·4 (-1·8, 2·6) 0·75 
At 52 wk 7·9 (6·4, 9·5) 9·1 (7·5, 10·6) -1·1 (-3·3, 1·0) 0·31 
Over 52 12·7 (11·5, 14·0) 13·5 (12·2, 14·8) -0·7 (-2·5, 1·1) 0·44 
Secondary outcome: PRWE function subscale scored 
No. of 203 205   
At 6 wk 16·7 (14·9, 18·5) 20·5 (18·7, 22·3) -3·8 (-6·3, -1·3) 0·003 
At 12 wk 8·1 (6·6, 9·5) 11·5 (10·0, 13·0) -3·4 (-5·6, -1·3) 0·001 
At 26 wk 5·4 (4·1, 6·6) 6·0 (4·7, 7·3) -0·6 (-2·4, 1·2) 0·52 
At 52 wk 3·9 (2·7, 5·1) 4·9 (3·7, 6·1) -1·0 (-2·6, 0·7) 0·25 
Over 52 8·6 (7·5, 9·7) 10·8 (9·7, 12·0) -2·2 (-3·8, -0·6) 0·01 
Secondary outcome: SF-12 mental component scoree 
No. of 202 206   
At 6 wk 49·7 (48·1, 51·3) 49·1 (47·5, 50·7) 0·5 (-1·7, 2·8) 0·63 
At 12 wk 50·6 (49·0, 52·1) 50·7 (49·1, 52·3) -0·2 (-2·4, 2·1) 0·88 
At 26 wk 51·0 (49·4, 52·6) 51·6 (49·9, 53·3) -0·6 (-3·0, 1·7) 0·60 
At 52 wk 51·0 (49·6, 52·5) 52·3 (50·8, 53·7) -1·2 (-3·3, 0·8) 0·24 
Over 52 50·6 (49·3, 51·8) 50·9 (49·7, 52·2) -0·4 (-2·2, 1·4) 0·69 
Secondary outcome: SF-12 physical component scoree 
No. of 202 206   
At 6 wk 43·9 (42·7, 45·1) 43·4 (42·2, 44·6) 0·5 (-1·2, 2·2) 0·59 
At 12 wk 49·8 (48·7, 50·9) 47·6 (46·5, 48·8) 2·2 (0·6, 3·8) 0·01 
At 26 wk 51·6 (50·5, 52·7) 51·6 (50·5, 52·8) -0·0 (-1·6, 1·5) 0·95 
At 52 wk 53·1 (52·1, 54·2) 51·5 (50·5, 52·6) 1·6 (0·2, 3·1) 0·03 
Over 52 49·6 (48·8, 50·4) 48·5 (47·7, 49·3) 1·1 (-0·1, 2·2) 0·08 
Secondary outcome: grip strength (kg) for affected wrist 
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No. of 201 206   
At 6 wk 23·8 (22·0, 25·6) 19·4 (17·6, 21·2) 4·4 (1·8, 6·9) 0·001 
At 12 wk 30·9 (29·0, 32·8) 28·3 (26·4, 30·2) 2·6 (-0·1, 5·3) 0·06 
At 52 wk 37·0 (35·1, 39·0) 38·0 (36·1, 40·0) -1·0 (-3·7, 1·7) 0·48 
Over 52 30·1 (28·5, 31·7) 27·9 (26·3, 29·5) 2·0 (-0·3, 4·2) 0·08 
a adjusted mean and 95% confidence interval, unless otherwise stated. All models specified as follows for 677 
relevant outcome: mixed-effect linear regression model adjusted, as fixed effects, for group (surgery, cast 678 
immobilization), time (6, 12, 26, 52 weeks), group x time interaction, age, baseline fracture displacement (<1 679 
mm, 1-2 mm) and dominance of injured limb (yes, no) with participant as a random effect  680 
b The “Cast immobilization” group was the standard clinical pathway using cast immobilisation initially and 681 
expecting suspected non-unions to be confirmed on imaging and immediately fixed. 682 
c Score range 0-100; lower score indicates better outcome 683 
dScore range 0-50; lower score indicates better outcome 684 
e 0 (lowest level of health) to 100 (highest level of health) 685 
  686 
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Table 3. Summary of union assessment by time point and randomised group 687 








At 6 wk, No. (%) Union 47 (21·5) 26 (11·8) 73 (16·6) 
 Almost full 
union 81 (37·0) 73 (33·2) 154 (35·1) 
 Partial union 47 (21·5) 70 (31·8) 117 (26·7) 
 Slight union 11 (5·0) 23 (10·5) 34 (7·7) 
 Non-union 2 (0·9) 9 (4·1) 11 (2·5) 
 Missing 31 (14·2) 19 (8·6) 50 (11·4) 
At 12 wk, No. 
(%) 
Union 
102 (46·6) 63 (28·6) 165 (37·6) 
 Almost full 
union 45 (20·5) 44 (20·0) 89 (20·3) 
 Partial union 15 (6·8) 33 (15·0) 48 (10·9) 
 Slight union 7 (3·2) 13 (5·9) 20 (4·6) 
 Non-union 0 (0·0) 10 (4·5) 10 (2·3) 
 Missing 50 (22·8) 57 (25·9) 107 (24·4) 
At 52 wk, No. 
(%) 
Union 
93 (42·5) 72 (32·7) 165 (37·6) 
 Almost full 
union 64 (29·2) 59 (26·8) 123 (28) 
 Partial union 3 (1·4) 10 (4·5) 13 (3) 
 Slight union 3 (1·4) 5 (2·3) 8 (1·8) 
 Non-union 1 (0·5) 4 (1·8) 5 (1·1) 
 Missing 55 (25·1) 70 (31·8) 125 (28·5) 
a 6 and 12 weeks from radiographic images, 52 weeks from CT unless missing in which case radiographic 
imaging was considered; b union on CT measured as a percentage (0-100%), and categorised as: 0% = non-
union, >0-20% = slight union, >20-70% = partial union, >70-100% (but not including 100) = mostly full union, 
and 100% = union 
c The “Cast immobilization” group was the standard clinical pathway using cast immobilisation initially and 
expecting suspected non-unions to be confirmed on imaging and immediately fixed. 
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Table 4. Participant reported time off work (days) due to the injury 690 
 








































0 (0, 0) 
75·8 149 
4·9 (10·9) 
0 (0, 2) 
67·1 310 
3·7 (9·4) 






0 (0, 0) 
90·1 135 
3·7 (14·9) 
0 (0, 0) 
88·9 277 
2·8 (12·7) 






0 (0, 0) 
91·5 160 
1·9 (14·7) 
0 (0, 0) 
91·3 324 
1·7 (12·8) 












5 (0, 25) 
33·2 
aThe “Cast immobilization” group was the standard clinical pathway using cast immobilisation initially and 691 










Figure 2: Adjusted mean PRWE scores (with 95% CIs) for primary analysis over time 
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Supplementary Table 1. Baseline fracture details for all randomised patients and those 
included in the primary analysis, by treatment group 
 

















score       
Mean (SD) 
3·1 (10·8) 
3·6 (11·8) 3·4 
(11·3) 
3·3 
(11·2) 3·8 (12·2) 3·5 (11·7) 
Median (IQR) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 
Baseline (post-
injury) PRWE 
score       
Mean (SD) 73·9 (19·8) 73·2 (17·4) 73·5 
(18·6) 
73·8 
(20·1) 73·4 (17·3) 
73·6 
(18·8) 
Median (IQR) 78·5 (65·5, 
87·5) 










injuryc       
Mean (SD) 
5·1 (3·1) 5·3 (3·3) 
5·2 
(3·2) 4·9 (3·0) 5·4 (3·3) 5·2 (3·2) 
Median (IQR) 5 (3, 7) 5 (3, 8) 5 (3, 7) 4 (2, 7) 5 (3, 8) 5 (3, 7) 
Affected wrist, 
No. (%)       
Left 





110 (53·7) 220 
(53·9) 
Right 
104 (47·5) 102 (46·4) 
206 
(46·9) 
93 (45·8) 95 (46·3) 188 
(46·1) 
Missing 0 (0·0) 0 (0·0) 0 (0·0) 0 (0·0) 0 (0·0) 0 (0·0) 
Dominant 
Hand, No. (%)       
Yes 
100 (45·7) 95 (43·2) 
195 








(54·7) 116 (56·6) 
227 
(55·6) 
Missing 2 (0·9) 0 (0·0) 2 (0·5) 0 (0·0) 0 (0·0) 0 (0·0) 
Fracture 
displacement, 
No. (%)       
No displacement 








(≥1mm, ≤2mm) 84 (38·4) 86 (39·1) 
170 




problems on       
 30 
 















same side, No. 
(%) 
Yes 
43 (19·6) 45 (20·5) 
88 
(20·0) 43 (21·2) 42 (20·5) 85 (20·8) 
No 




(78·3) 161 (78·5) 
320 
(78·4) 
Missing 3 (1·4) 2 (0·9) 5 (1·1) 1 (0·5) 2 (1·0) 3 (0·7) 
Injury 
mechanism, No. 




running 92 (42·0) 91 (41·4) 
183 
(41·7) 85 (41·9) 82 (40·0) 
167 
(40·9) 
Fall from height   
28 (12·8) 34 (15·5) 
62 
(14·1) 26 (12·8) 31 (15·1) 57 (14·0) 
Fall from 
moving object 42 (19·2) 31 (14·1) 
73 
(16·6) 41 (20·2) 31 (15·1) 72 (17·6) 
Hit on palm of 
hand 36 (16·4) 34 (15·5) 
70 
(15·9) 34 (16·7) 34 (16·6) 68 (16·7) 
Punched 
something 4 (1·8) 12 (5·5) 16 (3·6) 4 (2·0) 10 (4·9) 14 (3·4) 
Road traffic 
accident 9 (4·1) 8 (3·6) 17 (3·9) 9 (4·4) 7 (3·4) 16 (3·9) 
Other 6 (2·7) 10 (4·5) 16 (3·6) 4 (2·0) 10 (4·9) 14 (3·4) 
Missing  2 (0·9) 0 (0·0) 2 (0·5) 0 (0·0) 0 (0·0) 0 (0·0) 
Treatment 
preference, No. 
(%)       
Surgery 
93 (42·5) 101 (45·9) 
194 
(44·2) 89 (43·8) 96 (46·8) 
185 
(45·3) 
No surgery 13 (5·9) 19 (8·6) 32 (7·3) 11 (5·4) 16 (7·8) 27 (6·6) 
No preference 




(50·2) 92 (44·9) 
194 
(47·5) 
Missing 3 (1·4) 1 (0·5) 4 (0·9) 1 (0·5) 1 (0·5) 2 (0·5) 
a Participants included in primary analysis if they provided valid PRWE data for at least one post-randomisation time 
point and complete covariate data; 
b The “Cast immobilization” group was the standard clinical pathway using cast immobilisation initially and expecting 
suspected non-unions to be confirmed on imaging and immediately fixed. 
c time from injury to screening; d response categories not mutually exclusive 

















Sex, No. (%)     
  Male 834 (79·7) 203 (74·6) 268 (79·8) 363 (82·7) 
  Female 210 (20·1) 66 (24·3) 68 (20·2) 76 (17·3) 
  Missing 3 (0·3) 3 (1·1) 0 (0·0) 0 (0·0) 
Age, y     
  N 1040 266 335 439 
  Mean (SD) 33·7 (14·8) 36·6 (17·5) 32·5 (14·6) 32·9 (12·7) 
  Median (IQR) 
 
29·2 (22·5, 41·6) 30·0 (23·4, 47·4) 28·2 (21·1, 39·8) 29·3 (23·1, 40·4) 
Days since injurya     
  N 1044 269 336 439 
  Mean (SD) 1·0 (1·8) 1·2 (2·5) 1·0 (1·5) 0·8 (1·4) 
  Median (IQR) 0 (0, 1) 0 (0, 1) 1 (0, 1) 1 (0, 1) 
Displacement 
involvementb, No. (%)     
  Displacement 342 (32·7) 61 (22·4) 111 (33·0)  170 (38·7) 
  No displacement 651 (62·2) 160 (58·8) 222 (66·1) 269 (61·3) 
  Missing 54 (5·2) 51 (18·8) 3 (0·9) 0 (0·0) 
SD, standard deviation 
a time from injury to first contact with NHS (presentation at A&E or other); this is consistent with the inclusion criterion 
for patients to present at a participating site within two weeks of injury 
b as recorded on the Study Eligibility Form 
 
Supplementary Table 3: Treatment received - surgery group (n=219) 
Treatment 
pathway 
Definition of pathway N (%) Further details 
Crossover Participant immediately 
switched to plaster cast 
following consent and 
randomisation, no surgery 
31 (14·2) • Thirty participants received 
plaster cast (n=16), splint 
(n=3), or combination both 
(n=11), for a median of 52 days 
(range 9-84) post-
randomisation. 
• One participant did not receive 
any treatment as no fracture 
was observed on CT scan.  
Routine 
treatment 
Participant had one surgery 
within the 12 months from 
randomisation and no 
subsequent plaster cast and/or 
splint  
24 (11·0) • Surgery took place a median of 
4 days (range 0-9) post-
randomisation, no subsequent 




Participant had surgery and 
subsequent plaster cast and/or 
splint due to treatment failure 
e.g. poor stability from surgery 





Participant had surgery and 
subsequent plaster cast and/or 




• Surgery took place a median of 
4 days (range 0-15) post-
randomisation. 
• All received plaster cast 
(n=23), splint (n=40) or a 
combination of both (n=93) for 
a median of 37 days (range 2-
89) following surgery. 
Participant had index surgery 
but there was subsequent 
evidence of non-union, so was 
offered further surgery 
2 (0·9) • One participant received two 
surgeries within 12 months 
from randomisation (259 days 
after initial surgery); plaster 
cast worn for 17 days after 
surgery, followed by a splint. 
• One participant underwent 
three surgeries within 12 
months from randomisation; 
the second taking place 176 
days after the index surgery, 
and the third 125 days after the 
second surgery. 
Participant had index surgery 
and received further surgery 
(not for non-union) 
6 (2·7) • Revision surgery (n=1), or for 
removal of screw (n=5)  
• All received a splint (n=2) or a 
combination of plaster cast and 
splint (n=4) for a median of 44 
days (range 22-105) following 
their index surgery. 
• All underwent only one further 
surgery within 12 months from 
randomisation; this took place a 
median of 235 days (range 97-
347) after index surgery. 
 
Supplementary Table 4: Treatment received – plaster cast group (n=220) 
Treatment 
pathway 
Definition of pathway N (%) Further details 
Crossover Participant immediately 
switched to surgery following 
randomisation 
6 (2·7) • Surgery took place a median 
of 9 days (range 0-24) post-
randomisation. 
• Participants received a plaster 
cast (n=3), a splint (n=1) or a 
combination of both (n=2) for 
a median of 41 days (range 




conservatively – no surgery 
193 
(87·7) 
• 192 participants received a 
plaster cast (n=109) or a 
combination of plaster cast 
and splint (n=83) for a median 
of 43 days (range 7-101) post-
randomisation. 
• One participant was followed 
up at a different hospital so 
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treatment was unknown, but 
was immobilised in plaster 
cast at enrolment to the trial. 
Treatment 
failure 
Surgery undertaken to 
stabilise the fracture (before 
five weeks from 
randomisation). This is not a 
cross-over because the patient 
did have a plaster cast 
applied. 
1 (0·5) • Plaster cast worn following 
randomisation but fracture 
seen to be displacing so 
surgical fixation undertaken 
29 days post-randomisation 
and a splint was worn 
thereafter (unknown length of 
time). 
• Surgery was undertaken to 
remove the screw 96 days 






Surgery was undertaken after 
five weeks from 
randomisation – not owing to 
a failure to unite 
1 (0·5) • One participant received 
surgery within 6 months of 
randomisation at a non-






(after five weeks 
post-
randomisation) 
as per specified 
treatment 
pathway because 
of failure to 
unite. 
Surgery was not received 2 (0·9) • Operation was scheduled but 
then delayed, participant self-
discharged after wait and 
declined all further 
treatment/offers of surgery. 
• Non-union suspected at 12 
weeks but the surgeon 
decided not to operate. 
One surgery performed within 
12 months of randomisation 
16 (7·3) • 13 received urgent fixation of 
non-union (within 6 months 
of randomisation).   
• Three participants received 
late fixation, between 6 and 
12 months after 
randomisation. The reasons 
for two of these are unknown; 
one participant opted to attend 
a private hospital for their 
fixation as they were told 
there would be a 4-5 month 
wait for surgery at treating 
centre. 
Two or more surgeries were 
performed within 12 months 
of randomisation 
1 (0·5) • Participant received initial 
surgical fixation within 3 
months of randomisation, a 
further surgery 6 months later 
for persistent non-union and 
surgery to remove the wires 
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from the second operation a 
month later.   
 
Sensitivity analyses for the primary outcome 
 
Timing of data collection 
The primary analysis model was repeated only including data collected one week either side of the 6-week time 
point, two weeks either side of the 12-week time point, 6 weeks either side of the 26-week time point, and eight 
weeks either side of the 52-week time point. 
 
Displacement and absence of fracture assessed by independent review of baseline imaging data 
Discrepancies between the displacement of the fracture (<1 mm, or 1-2 mm inclusive) judged by the treating 
clinician on plain radiographs and stratified on in the randomisation, and the judgement agreed by three 
independent reviewers of the baseline CT scans and radiographs were observed.  Baseline radiographic 
images were available and reviewed for all but one participant (in the surgery arm).  Baseline CT images 
were available and reviewed for 431 participants (surgery n=214, 97%; cast immobilization n=217, 99%).  
Both baseline and CT images were reviewed for 431 (98%) participants, radiographs only for 7 (2%) 
participants, and neither for one participant (<1%). The maximum fracture displacement, in millimetres, 
observed on either the CT or radiographic images was identified and used to categorise the participant’s 
fracture displacement as: <1 mm; 1-2 mm, inclusive; and >2 mm. Overall, 213 (82%) of the 261 fractures 
that were deemed not to be displaced by the treating clinician at baseline were classified as not displaced (<1 
mm) on review, 39 (15%) as displaced 1-2 mm, 8 (3%) as >2 mm, and 1 (<1%) missing. Of the 178 fractures 
that were deemed to be displaced (1-2 mm) by the treating clinician at baseline, 112 (63%) were classified as 
not displaced (<1 mm) on review, 47 (26%) as displaced 1-2 mm, and 19 (11%) as >2 mm.   
 
The primary analysis model was repeated including, as a fixed effect covariate, baseline fracture 
displacement judged by the three raters instead of that randomised on, producing very similar results to the 
primary analysis. 
 
Consensus was reached between the three raters that displacement of the fracture was greater than 2 mm for 
27 (6%) randomised participants. A fracture could be seen on radiographic imaging for all but one of the 438 
participants (n=437, 100%) for whom these data were available, and on CT imaging for 426 (99%) of 431 
participants. For four of the five participants for whom a fracture could not be seen on their CT, it could be 
seen on the radiographic images; thus, consensus was reached between the three raters that only one 
participant did not actually have a fracture (participant allocated to surgery group). Sensitivity analyses of the 
primary outcome model were conducted that excluded these participants. 
 
Supplementary Table 5. Sensitivity analyses for the primary outcome 
 
Mean (95% CI)a 







Data derived by multiple imputationa 
No. of patients 219 220   
At 6 wk 35·1 (32·1, 38·1) 39·8 (36·7, 42·9) -4·7 (-9·0, -0·5) 0·03 
At 12 wk 20·7 (17·9, 23·6) 26·6 (23·7, 29·5) -5·9 (-9·9, -1·9) 0·007 
At 26 wk 16·1 (13·4, 18·8) 16·4 (13·7, 19·2) -0·3 (-4·2, 3·5) 0·87 
At 52 wk 12·0 (9·3, 14·6) 14·1 (11·4, 16·8) -2·1 (-5·9, 1·6) 0·26 
Adjusting for clustering by site 
No. of patients 203 205   
At 6 wk 36·2 (32·6, 39·8) 40·2 (36·6, 43·8) -4·0 (-8·2, 0·3) 0·07 
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At 12 wk 21·6 (18·1, 25·1) 27·0 (23·4, 30·6) -5·4 (-9·5, -1·2) 0·01 
At 26 wk 16·8 (13·5, 20·1) 16·9 (13·6, 20·3) -0·1 (-3·9, 3·7) 0·96 
At 52 wk 12·5 (9·2, 15·7) 14·4 (11·1, 17·7) -1·9 (-5·6, 1·8) 0·31 
Overall 21·9 (18·8, 24·9) 24·8 (21·7, 27·8) -2·8 (-6·1, 0·4) 0·09 
Adjusted for smoking status (post-hoc) 
No. of patients 202 204   
At 6 wk 35·3 (32·3, 38·3) 40·0 (36·9, 43·0) -4·7 (-9·0, -0·4) 0·03 
At 12 wk 20·7 (17·8, 23·7) 26·8 (23·8, 29·8) -6·0 (-10·2, -1·8) 0·01 
At 26 wk 15·9 (13·2, 18·6) 16·7 (14·0, 19·5) -0·8 (-4·7, 3·0) 0·67 
At 52 wk 11·3 (8·8, 13·9) 14·2 (11·5, 16·8) -2·8 (-6·5, 0·9) 0·14 
Overall 20·9 (18·6, 23·2) 24·6 (22·2, 26·9) -3·6 (-6·9, -0·3) 0·03 
Timing of data collection 
No. of patients 190 190   
At 6 wk 37·3 (33·9, 40·7) 37·7 (34·2, 41·2) -0·4 (-5·3, 4·4) 0·86 
At 12 wk 20·6 (17·5, 23·8) 26·4 (23·1, 29·7) -5·7 (-10·3, -1·2) 0·01 
At 26 wk 15·2 (12·5, 17·9) 15·4 (12·7, 18·1) -0·2 (-4·0, 3·6) 0·93 
At 52 wk 10·8 (8·2, 13·3) 13·8 (11·2, 16·5) -3·1 (-6·7, 0·6) 0·10 
Overall 19·9 (17·6, 22·2) 22·2 (19·9, 24·5) -2·4 (-5·6, 0·9) 0·16 
Including displacement as agreed by three independent raters 
No. of patients 203 205   
At 6 wk 35·5 (32·5, 38·5) 39·8 (36·8, 42·8) -4·3 (-8·5, -0·0) 0·05 
At 12 wk 21·0 (18·0, 23·9) 26·6 (23·6, 29·6) -5·6 (-9·8, -1·4) 0·01 
At 26 wk 16·2 (13·6, 18·9) 16·5 (13·8, 19·2) -0·3 (-4·1, 3·6) 0·89 
At 52 wk 11·9 (9·3, 14·5) 13·9 (11·3, 16·6) -2·1 (-5·8, 1·6) 0·27 
Overall 21·2 (18·9, 23·5) 24·4 (22·0, 26·7) -3·1 (-6·3, 0·2) 0·07 
Excluding those with no fracture 
No. of patients 202 205   
At 6 wk 35·7 (32·6, 38·7) 39·8 (36·8, 42·8) -4·1 (-8·4, 0·1) 0·06 
At 12 wk 21·1 (18·1, 24·0) 26·6 (23·6, 29·6) -5·5 (-9·7, -1·3) 0·01 
At 26 wk 16·3 (13·6, 19·0) 16·5 (13·8, 19·2) -0·2 (-4·1, 3·6) 0·91 
At 52 wk 11·9 (9·3, 14·6) 14·0 (11·3, 16·6) -2·0 (-5·8, 1·7) 0·29 
Overall 21·3 (19·0, 23·6) 24·4 (22·0, 26·7) -3·0 (-6·3, 0·3) 0·08 
Excluding those with displacement >2mm 
No. of patients 191 192   
At 6 wk 35·0 (31·9, 38·0) 39·8 (36·7, 42·9) -4·8 (-9·2, -0·5) 0·03 
At 12 wk 20·7 (17·6, 23·7) 26·2 (23·1, 29·3) -5·6 (-9·9, -1·3) 0·01 
At 26 wk 15·7 (13·0, 18·3) 16·3 (13·6, 19·0) -0·6 (-4·4, 3·2) 0·76 
At 52 wk 11·4 (8·8, 13·9) 13·7 (11·0, 16·3) -2·3 (-6·0, 1·4) 0·22 
Overall 20·7 (18·4, 23·0) 24·1 (21·7, 26·4) -3·3 (-6·6, 0·0) 0·05 







Supplementary Table 6. Wrist range of movement and grip strength of affected wrist 
Wrist range of movement and grip 





Baseline  N=216 N=218 N=434 
Beighton Laxity Mean (SD) 1·1 (2·0) 0·9 (1·7) 1·0 (1·8) 
Score Median (IQR) 0·0 (0·0, 2·0) 0·0 (0·0, 1·0) 0·0 (0·0, 1·0) 
 Min, max (0·0, 10·0) (0·0, 8·0) (0·0, 10·0) 
Extension (°) Mean (SD) 32·0 (18·6) 28·9 (17·2) 30·4 (17·9) 
 Median (IQR) 30·0 (20·0, 42·0) 30·0 (18·0, 40·0) 30·0 (20·0, 40·0) 
 Min, max (0·0, 135·0) (-15·0, 90·0) (-15·0, 135·0) 
Flexion (°) Mean (SD) 35·0 (25·5) 34·9 (21·7) 35·0 (23·6) 
 Median (IQR) 30·0 (20·0, 45·0) 35·0 (22·0, 44·0) 32·0 (20·0, 45·0) 
 Min, max (0·0, 160·0) (0·0, 162·0) (0·0, 162·0) 
Radial Deviation (°) Mean (SD) 14·3 (9·5) 14·3 (9·6) 14·3 (9·6) 
 Median (IQR) 13·0 (10·0, 20·0) 14·0 (9·0, 20·0) 13·0 (9·0, 20·0) 
 Min, max (0·0, 60·0) (0·0, 70·0) (0·0, 70·0) 
Ulnar Deviation (°) Mean (SD) 18·0 (10·9) 18·6 (11·0) 18·3 (10·9) 
 Median (IQR) 17·0 (10·0, 22·5) 18·0 (10·0, 25·0) 18·0 (10·0, 25·0) 
 Min, max (0·0, 70·0) (0·0, 60·0) (0·0, 70·0) 
Forearm Rotation  Mean (SD) 66·9 (26·7) 63·6 (27·8) 65·3 (27·3) 
Supination (°) Median (IQR) 75·0 (56·5, 85·0) 70·0 (50·0, 85·0) 73·0 (50·0, 85·0) 
 Min, max (0·0, 124·0) (-10·0, 118·0) (-10·0, 124·0) 
Forearm Rotation  Mean (SD) 72·2 (23·1) 71·2 (25·0) 71·7 (24·0) 
Pronation (°) Median (IQR) 80·0 (67·5, 90·0) 80·0 (68·5, 90·0) 80·0 (68·0, 90·0) 
 Min, max (0·0, 100·0) (0·0, 105·0) (0·0, 105·0) 
Grip Strength (kg) Mean (SD) 9·6 (10·0) 9·8 (10·6) 9·7 (10·3) 
 Median (IQR) 6·0 (2·0, 15·3) 7·0 (2·0, 12·7) 6·7 (2·0, 14·4) 
 Min, max (0·0, 61·7) (0·0, 58·0) (0·0, 61·7) 
6 weeks N=189 N=200 N=389 
Extension (°) Mean (SD) 51·0 (20·2) 40·0 (18·3) 45·4 (20·0) 
 Median (IQR) 50·0 (38·0, 60·0) 40·0 (28·0, 50·0) 45·0 (30·0, 56·0) 
 Min, max (5·0, 135·0) (0·0, 90·0) (0·0, 135·0) 
Flexion (°) Mean (SD) 51·6 (28·3) 40·1 (23·4) 45·7 (26·5) 
 Median (IQR) 49·0 (30·0, 65·0) 35·0 (25·0, 50·0) 40·0 (30·0, 60·0) 
 Min, max (5·0, 162·0) (-5·0, 158·0) (-5·0, 162·0) 
Radial Deviation (°) Mean (SD) 21·7 (10·7) 21·3 (12·8) 21·5 (11·8) 
 Median (IQR) 20·0 (15·0, 28·0) 20·0 (11·0, 28·0) 20·0 (13·0, 28·0) 
 Min, max (0·0, 60·0) (0·0, 70·0) (0·0, 70·0) 
Ulnar Deviation (°) Mean (SD) 29·3 (12·1) 23·5 (13·0) 26·3 (12·9) 
 Median (IQR) 30·0 (20·0, 38·0) 20·0 (15·0, 30·0) 25·0 (18·0, 35·0) 
 Min, max (1·0, 60·0) (0·0, 70·0) (0·0, 70·0) 
Forearm Rotation  Mean (SD) 82·4 (15·7) 74·9 (20·3) 78·5 (18·6) 
Supination (°) Median (IQR) 90·0 (80·0, 90·0) 80·0 (65·0, 90·0) 85·0 (72·0, 90·0) 
 Min, max (0·0, 131·0) (0·0, 108·0) (0·0, 131·0) 
Forearm Rotation  Mean (SD) 82·8 (14·4) 80·1 (15·5) 81·4 (15·0) 
Pronation (°) Median (IQR) 90·0 (80·0, 90·0) 85·0 (75·0, 90·0) 90·0 (80·0, 90·0) 
 Min, max (0·0, 110·0) (10·0, 104·0) (0·0, 110·0) 
Grip Strength (kg) Mean (SD) 24·1 (12·7) 20·1 (14·0) 22·0 (13·5) 
 Median (IQR) 23·3 (15·3, 32·7) 18·2 (9·3, 28·7) 20·0 (11·3, 30·7) 
 Min, max (0·0, 77·3) (0·0, 81·7) (0·0, 81·7) 
12 weeks N=172 N=164 N=336 
Extension (°) Mean (SD) 61·1 (17·7) 56·9 (19·5) 59·1 (18·7) 
 Median (IQR) 60·0 (50·0, 70·0) 55·0 (43·5, 70·0) 60·0 (45·0, 70·0) 
 Min, max (13·0, 125·0) (2·0, 125·0) (2·0, 125·0) 
Flexion (°) Mean (SD) 62·0 (23·7) 55·3 (22·3) 58·7 (23·2) 
 Median (IQR) 60·0 (45·0, 75·0) 55·0 (41·0, 70·0) 58·0 (45·0, 72·0) 
 Min, max (15·0, 144·0) (5·0, 144·0) (5·0, 144·0) 
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Radial Deviation (°) Mean (SD) 26·1 (12·7) 26·2 (14·5) 26·1 (13·6) 
 Median (IQR) 25·0 (18·0, 30·0) 23·0 (15·0, 32·0) 24·0 (18·0, 30·0) 
 Min, max (5·0, 80·0) (0·0, 80·0) (0·0, 80·0) 
Ulnar Deviation (°) Mean (SD) 35·4 (12·7) 31·6 (13·7) 33·5 (13·3) 
 Median (IQR) 35·0 (28·0, 40·0) 30·0 (22·0, 40·0) 31·0 (25·0, 40·0) 
 Min, max (10·0, 80·0) (0·0, 80·0) (0·0, 80·0) 
Forearm Rotation  Mean (SD) 87·1 (13·8) 82·3 (18·2) 84·7 (16·3) 
Supination (°) Median (IQR) 90·0 (85·0, 90·0) 90·0 (80·0, 90·0) 90·0 (80·0, 90·0) 
 Min, max (10·0, 140·0) (0·0, 126·0) (0·0, 140·0) 
Forearm Rotation  Mean (SD) 86·5 (8·5) 83·4 (13·8) 85·0 (11·5) 
Pronation (°) Median (IQR) 90·0 (85·0, 90·0) 90·0 (80·0, 90·0) 90·0 (80·0, 90·0) 
 Min, max (26·0, 104·0) (0·0, 120·0) (0·0, 120·0) 
Grip Strength (kg) Mean (SD) 30·8 (12·5) 28·2 (14·4) 29·5 (13·5) 
 Median (IQR) 29·3 (22·3, 39·3) 28·5 (18·7, 37·8) 28·7 (20·0, 38·7) 
 Min, max (0·0, 82·0) (0·0, 89·0) (0·0, 89·0) 
52 weeks N=163 N=146 N=309 
Extension (°) Mean (SD) 68·4 (21·0) 68·8 (15·5) 68·6 (18·6) 
 Median (IQR) 70·0 (56·0, 80·0) 70·0 (56·0, 80·0) 70·0 (56·0, 80·0) 
 Min, max (15·0, 140·0) (40·0, 115·0) (15·0, 140·0) 
Flexion (°) Mean (SD) 69·8 (20·3) 68·4 (16·4) 69·1 (18·5) 
 Median (IQR) 70·0 (55·0, 85·0) 70·0 (60·0, 80·0) 70·0 (58·0, 80·0) 
 Min, max (20·0, 152·0) (22·0, 105·0) (20·0, 152·0) 
Radial Deviation (°) Mean (SD) 32·2 (17·4) 32·5 (14·5) 32·4 (16·1) 
 Median (IQR) 28·0 (20·0, 40·0) 30·0 (22·0, 40·0) 30·0 (20·0, 40·0) 
 Min, max (6·0, 90·0) (8·0, 80·0) (6·0, 90·0) 
Ulnar Deviation (°) Mean (SD) 40·6 (14·8) 39·9 (13·7) 40·3 (14·3) 
 Median (IQR) 40·0 (30·0, 50·0) 40·0 (30·0, 49·0) 40·0 (30·0, 50·0) 
 Min, max (8·0, 90·0) (12·0, 80·0) (8·0, 90·0) 
Forearm Rotation  Mean (SD) 88·3 (13·3) 85·2 (13·9) 86·8 (13·6) 
Supination (°) Median (IQR) 90·0 (86·0, 90·0) 90·0 (80·0, 90·0) 90·0 (85·0, 90·0) 
 Min, max (30·0, 136·0) (30·0, 122·0) (30·0, 136·0) 
Forearm Rotation  Mean (SD) 86·8 (10·5) 86·2 (9·5) 86·5 (10·0) 
Pronation (°) Median (IQR) 90·0 (85·0, 90·0) 90·0 (85·0, 90·0) 90·0 (85·0, 90·0) 
 Min, max (5·0, 114·0) (40·0, 109·0) (5·0, 114·0) 
Grip Strength (kg) Mean (SD) 36·9 (12·7) 37·4 (14·2) 37·2 (13·4) 
 Median (IQR) 36·2 (28·7, 44·8) 38·5 (28·7, 46·2) 37·3 (28·7, 45·2) 
 Min, max (10·3, 109·7) (4·7, 88·3) (4·7, 109·7) 
 
Malunion 
Scaphoid height and length was measured by the three independent raters of the CT and plain radiographs.  
Malunion was determined by calculating the ratio of the scaphoid height to length, and determined using 
thresholds of both 0·6 and 0·7 (Supplementary Table 4).  ten Berg et al.14 noted a ratio of 0·69 as the upper 95% 
CI of a normal population so we used this (0·7) to define malunion in addition to the 0·6 we proposed in our 
protocol. By default, more participants are classified as having malunion using the 0·6 threshold than 0·7.  
Considering those with non-missing data only, at 6 weeks, 175 (94%) participants in the surgery group and 180 
(90%) in the cast immobilization group had malunion based on the 0·6 threshold.  At 0·7, the figures are 52 
(28%) and 51 (26%), respectively.  Malunion at both thresholds remained reasonably steady in both groups at 6, 
12 and 52 weeks on radiographic images.  However, at 52 weeks, on CT, the rate of malunion occurred in 60 
(38%) participants in the surgery group and 45 (33%) in the cast immobilization group at the 0·6 threshold, and 









Supplementary Table 7. Malunion assessed at thresholds of scaphoid ratio height to length of 0·6 and 0·7 
by randomised group and time point 








0·6 threshold     
Baseline No malunion 30 (13·7) 28 (12·7) 58 (13·2) 
(Radiographs) Malunion 182 (83·1) 190 (86·4) 372 (84·7) 
 Missing 7 (3·2) 2 (0·9) 9 (2·1) 
Baseline No malunion 154 (70·3) 160 (72·7) 314 (71·5) 
(CT) Malunion 63 (28·8) 54 (24·5) 117 (26·7) 
 Missing 2 (0·9) 6 (2·7) 8 (1·8) 
6 weeks No malunion 12 (5·5) 20 (9·1) 32 (7·3) 
 Malunion 175 (79·9) 180 (81·8) 355 (80·9) 
 Missing 32 (14·6) 20 (9·1) 52 (11·8) 
12 weeks No malunion 10 (4·6) 12 (5·5) 22 (5·0) 
 Malunion 159 (72·6) 151 (68·6) 310 (70·6) 
 Missing 50 (22·8) 57 (25·9) 107 (24·4) 
52 weeks No malunion 9 (4·1) 13 (5·9) 22 (5·0) 
(Radiographs) Malunion 148 (67·6) 128 (58·2) 276 (62·9) 
 Missing 62 (28·3) 79 (35·9) 141 (32·1) 
52 weeks No malunion 97 (44·3) 90 (40·9) 187 (42·6) 
(CT) Malunion 60 (27·4) 45 (20·5) 105 (23·9) 
 Missing 62 (28·3) 85 (38·6) 147 (33·5) 
0·7 threshold     
Baseline No malunion 167 (76·3) 173 (78·6) 340 (77·4) 
(Radiographs) Malunion 45 (20·5) 45 (20·5) 90 (20·5) 
 Missing 7 (3·2) 2 (0·9) 9 (2·1) 
Baseline No malunion 214 (97·7) 212 (96·4) 426 (97) 
(CT) Malunion 3 (1·4) 2 (0·9) 5 (1·1) 
 Missing 2 (0·9) 6 (2·7) 8 (1·8) 
6 weeks No malunion 135 (61·6) 149 (67·7) 284 (64·7) 
 Malunion 52 (23·7) 51 (23·2) 103 (23·5) 
 Missing 32 (14·6) 20 (9·1) 52 (11·8) 
12 weeks No malunion 117 (53·4) 118 (53·6) 235 (53·5) 
 Malunion 52 (23·7) 45 (20·5) 97 (22·1) 
 Missing 50 (22·8) 57 (25·9) 107 (24·4) 
52 weeks No malunion 96 (43·8) 101 (45·9) 197 (44·9) 
(Radiographs) Malunion 61 (27·9) 40 (18·2) 101 (23·0) 
 Missing 62 (28·3) 79 (35·9) 141 (32·1) 
52 weeks No malunion 150 (68·5) 128 (58·2) 278 (63·3) 
(CT) Malunion 7 (3·2) 7 (3·2) 14 (3·2) 









Supplementary Table 8. Non-serious adverse events by randomised group 








No. participants reporting ≥1 adverse events, No. (%)^ 24 (11·0) 29 (13·2) 53 (12·1) 
Total number of non-serious adverse events 30 36 66 
Number of non-serious events per participant, No. (%)^    
0 195 (89·0) 191 (86·8) 386 (87·9) 
1 19 (8·7) 23 (10·5) 42 (9·6) 
2 4 (1·8) 5 (2·3) 9 (2·1) 
3 1 (0·5) 1 (0·5) 2 (0·5) 
Adverse events of anaesthesia and/or surgerya, No. (%)¥    
Screw related complication 9 (30·0) 1 (2·8) 10 (15·2) 
Nerve or vessel event 4 (13·3) 1 (2·8) 5 (7·6) 
Infection 2 (6·7) 2 (5·6) 4 (6·1) 
Complex Regional Pain Syndrome 3 (10·0) 0 (0·0) 3 (4·6) 
Symptoms consistent with non-union 1 (3·3) 0 (0·0) 1 (1·5) 
Other 5 (16·7) 0 (0·0) 5 (7·6) 
Any of the above 24 (80·0) 4 (11·1) 28 (42·4) 
Adverse events of cast treatmenta, No. (%)¥    
Pain related to the cast 2 (6·7) 6 (16·7) 8 (12·1) 
Symptoms consistent with non-union 0 (0·0) 8 (22·2) 8 (12·1) 
Pressure sores 0 (0·0) 5 (13·9) 5 (7·6) 
Pain due to tight cast 1 (3·3) 2 (5·6) 3 (4·6) 
Soft cast/broken cast that leads to movement of wrist 0 (0·0) 2 (5·6) 2 (3·0) 
Any of the above 3 (3·0) 23 (63·9) 26 (39·4) 
Othera, No. (%)¥    
Reinjury 2 (6·7) 7 (19·4) 9 (13·6) 
Allergy to dressing 0 (0·0) 2 (5·6) 2 (3·0) 
Substance abuse 1 (3·3) 0 (0·0) 3 (1·5) 
Any of the above 3 (3·0) 9 (25·0) 12 (18·2) 
Gradingb, No. (%)¥    
Mild 22 (73·3) 28 (77·8) 50 (75·8) 
Moderate 7 (23·3) 7 (19·4) 14 (21·2) 
Severe 1 (3·3) 0 (0·0) 1 (1·5) 
Missing 0 (0·0) 1 (2·8) 1 (1·5) 
Causalityb, No. (%)¥    
Not related 2 (6·7) 8 (22·2) 10 (15·2) 
Unlikely to be related 2 (6·7) 2 (5·6) 4 (6·1) 
Possibly related 10 (33·3) 2 (5·6) 12 (18·2) 
Probably related 4 (13·3) 1 (2·8) 5 (7·6) 
Definitely related 12 (40·0) 23 (63·9) 35 (53·0) 
Expectednessb, No. (%)¥    
Expected 25 (83·3) 25 (69·4) 50 (75·8) 
Unexpected 5 (16·7) 11 (30·6) 16 (24·2) 
a retrospectively and independently classified by two clinicians, disagreements discussed and resolved; b 
classifications as provided on Adverse Event Initial Report Form by reporting clinician    







Supplementary Table 9. Serious adverse events by randomised group 








No. participants reporting ≥1 adverse events, No. (%)^ 3 (1·4) 0 (0·0) 0 (0·0) 
Total number of serious adverse events 3 0 0 
Number of serious events per participant, No. (%)^    
0 216 (98·6) 220 (100·0) 436 (99·3) 
1 3 (1·4) 0 (0·0) 3 (0·7) 
Type of eventb, No. (%)¥    
Hospitalisation 2 (66·7) 0 (0·0) 2 (66·7) 
Persistent or significant disability/incapacity 1 (33·3) 0 (0·0) 3 (33·3) 
Adverse events of anaesthesia and/or surgerya, No. (%)¥    
Anaesthetic complication 2 (66·7) 0 (0·0) 2 (66·7) 
Symptoms consistent with non-union 1 (33·3) 0 (0·0) 1 (33·3) 
Causalityb, No. (%)¥    
Definitely related 3 (100·0) 0 (0·0) 3 (100·0) 
Expectednessb, No. (%)¥    
Expected 1 (33·3) 0 (0·0) 1 (33·3) 
Unexpected 2 (66·7) 0 (0·0) 2 (66·7) 
Durationb, No. (%)¥    
≤24 hours 2 (66·7) 0 (0·0) 2 (66·7) 
>24 hours 1 (33·3) 0 (0·0) 1 (33·3) 
a retrospectively and independently classified by two clinicians, disagreements discussed and resolved; b 
classifications as provided on Adverse Event Initial Report Form by reporting clinician   
^ percentages out of number of randomised participants’ ¥ percentages out of number of events  
 
There was no evidence of a difference between the two groups in the overall rate of 
participants experiencing at least one surgical, medical or cast complication regardless of 
severity or impact up to 52 weeks (surgery group, n=39, 18%; plaster cast group, n=51, 23%, 
OR 0·72, 95% CI 0·45 to 1·15; p=0·17). 
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Supplementary Figure 1. Unadjusted mean PRWE scores (with 95% CIs) over time by 
patient treatment preference; fracture displacement at randomisation 
(a) No preference (b) Preference for surgery and (c) Preference for no surgery 
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